Oppenheimer Starts KERX, CLDX, PSTI, IMMU at Outperform, ONCY at Perform

Oppenheimer's Boris Peaker initiated coverage on a number of Biotech stocks Tuesday morning:

• KERYX Biopharma (Nasdaq: KERX) with an Outperform rating and a $7 price target
  
• Celldex (Nasdaq: CLDX) with an Outperform rating and a $6 price target
  
• Pluristem Therapeutics (Nasdaq: PSTI) with an Outperform rating and a $5 price target
  
• Immunomedics (Nasdaq: IMMU) with an Outperform rating and a $6 price target
  
• Oncolytics (Nasdaq: ONCY) with a Perform rating

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Raymond James Starts Southern California Bancorp (BCAL) at Outperform
• BMO Capital Starts D-Wave Quantum Inc. (QBTS) at Outperform
• BMO Capital Starts Skyworks Solutions (SWKS) at Market Perform